• 1
    Potter SR, Epstein JI, Partin AW. Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications. Rev Urol 2000; 2: 1905
  • 2
    Epstein JI, Partin AW, Potter SR, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology 2000; 56: 2838
  • 3
    D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95: 2816
  • 4
    Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61: 3659
  • 5
    Jhaveri FM, Klein EA. How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin Urol Oncol 1999; 17: 1304
  • 6
    Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA <10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006; 50: 2729
  • 7
    Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169: 84954
  • 8
    Freeman JA, Esrig D, Grossfeld GD, Stein JP, Chen SC, Young LL. Incidence of occult lymph node metastases in pathological stage C (pT3N0) prostate cancer. J Urol 1995; 154: 4748
  • 9
    Lowe BA, Lieberman SF. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 1997; 158: 14526
  • 10
    Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166: 220815
  • 11
    Fourcade OR, Richaud P, Coloby P, Malavaud B. Groupe des investigateurs français du programme EPC. Role of 150mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program. Prog Urol 2007; 17: 891910
  • 12
    Siddiqui SA, Boorjian SA, Blute ML et al. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int 2011; 107: 3838
  • 13
    Anscher MS, Robertson CN, Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys 1995; 33: 3743
  • 14
    Lee HM, Solan MJ, Lupinacci P, Gomella LG, Valicenti RK. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Urology 2004; 64: 849
  • 15
    Valicenti RK, Gomella LG, Ismail M, Mullholland SG, Petersen RO, Corn BW. Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control. Cancer 1998; 82: 190914
  • 16
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 2005; 61: 71424
  • 17
    Bolla M, Van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 5728
  • 18
    Swanson GP, Goldman B, Tangen CM et al. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from southwest oncology group 8794. J Urol 2008; 180: 24538
  • 19
    Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295300
  • 20
    Lawton CA, Winter K, Murray K et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 93746
  • 21
    Bloom KD, Richie JP, Schultz D, Renshaw A, Staegaert T, D’Amico AV. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology 2004; 63: 3336
  • 22
    Salomon L, Anastasiadis AG, Johnson CW et al. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology 2003; 62: 3049
  • 23
    Freedland SJ, Aronson WJ, Presti JC Jr et al. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer 2004; 100: 16338
  • 24
    Tefilli MV, Gheiler EL, Tiguert R et al. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol 1998; 160: 8026
  • 25
    Secin FP, Bianco FJ Jr, Vickers AJ et al. Cancer specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy. Cancer 2006; 106: 236975
  • 26
    Petrovich Z, Lieskovsky G, Langholz B, Jozsef G, Streeter OE Jr, Skinner DG. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 6009
  • 27
    Sofer M, Savoie M, Kim SS, Civantos F, Soloway MS. Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion. J Urol 2003; 169: 1536